Bio-Techne Corporation
Bio-Techne Reports Third Quarter Fiscal 2026 Results and Announces Cash Dividend
Summary
Bio-Techne Corporation reported its financial results for the third quarter of fiscal 2026, showing a 2% decline in reported and organic revenue to $311.4 million. GAAP earnings per share (EPS) increased to $0.32 from $0.14 in the same quarter last year, while adjusted EPS decreased to $0.53 from $0.56. The company also announced a cash dividend. Key segments saw mixed performance, with the Protein Sciences segment experiencing a 4% decline in organic revenue and the Diagnostics and Spatial Biology segment seeing a 3% increase. The company's strong operating discipline and financial flexibility position it well for long-term value creation.
Profitelligence Alerts
Get alerts for TECH
Be first to know when Bio-Techne Corporation files with the SEC.
Filing Categories
Advertisement
About Bio-Techne Corporation
Bio-Techne Corporation is a leading developer and manufacturer of high-quality biological products and solutions for the research and clinical diagnostic markets. The company specializes in providing an extensive range of biotechnological tools that support the advancement of life sciences. Key offerings include proteins, antibodies, assay kits, and laboratory services critical for scientific research and drug development. Bio-Techne operates across diverse sectors such as biotechnology, pharmaceuticals, academic research, and healthcare, supplying innovative solutions that facilitate groundbreaking research and therapeutic discoveries. Its products are essential in advancing modern biology and medicine, contributing to significant developments in areas like cancer research, immunology, and cell biology. Bio-Techne’s commitment to innovation and quality makes it a pivotal player in the biotechnology industry, elevating scientific discovery and fostering advancements in personalized medicine and diagnostics. With a strong global presence, Bio-Techne continues to impact the global life sciences landscape profoundly, upholding a legacy of excellence and reliability in the biotechnological sector.
Official SEC Documents
Advertisement